Dr. Reddy's Laboratories Ltd. (DRREDDY) Price & Analysis

Compare

9 Followers

DRREDDY Stock Chart & Stats

₹1280.40

₹4.55(0.33%)

At close: Jan 09 4:00 PM EST

₹1280.40

₹4.55(0.33%)

Day’s Range― - ―

52-Week Range₹1,025.90 - ₹1,377.95

Previous CloseN/A

Volume1.21M

Average Volume (3M)225.11K

Market Cap

₹1.06T

Enterprise Value₹1.12T

Total Cash (Recent Filing)₹82.59B

Total Debt (Recent Filing)₹79.34B

Price to Earnings (P/E)18.7

Beta0.76

Next Earnings

May 08, 2026

EPS Estimate

11.82

Next Dividend Ex-DateN/A

Dividend Yield0.63%

Share Statistics

EPS (TTM)14.52

Shares Outstanding834,591,300

10 Day Avg. Volume499,682

30 Day Avg. Volume225,111

Financial Highlights & Ratios

PEG Ratio11.98

Price to Book (P/B)2.88

Price to Sales (P/S)2.95

P/FCF Ratio50.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,425.00

Price Target Upside11.29% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High And Sustainable MarginsConsistently strong gross and net margins provide structural profitability advantages vs peers, enabling reinvestment in R&D, branded growth and capacity. High margins also create a buffer against pricing cycles, supporting durable cash generation and return metrics over the medium term.

Conservative Balance Sheet And LiquidityA net cash surplus and low leverage give management flexibility to fund capex, complete integrations, and sustain pipeline investments without immediate financing. This financial headroom lowers execution risk for launches and M&A, improving resilience to regulatory or market delays.

Diversified Growth Engines And Pipeline MomentumBroad exposure across branded India, emerging markets, generics, APIs, biosimilars and CDMO plus tangible semaglutide and abatacept progress reduces reliance on any single product. Multiple secular growth drivers and an active filing pipeline support sustained revenue diversification and secular growth over 2–3 years.

Bears Say

Weak Cash ConversionEarnings are not translating into proportional cash, indicating working‑capital or investment drains. Persistently low cash conversion constrains internal funding for R&D, capex and acquisitions, increases reliance on external financing and magnifies execution risk during margin or revenue pressure.

Margin Compression Post-LenalidomideA step‑down in high‑margin product revenue and broader pricing pressure reduces structural profitability, limiting free cash generation and ROCE. If mix shifts toward lower‑margin unbranded generics persist, reinvestment capacity and long‑term returns could be permanently impaired.

Regulatory Risk For Key Biologics And InspectionsRegulatory setbacks and facility observations can materially delay high‑value biologic launches, compress projected revenue and ROI from biosimilars, and strain partner relationships. Prolonged re‑inspections or CRLs increase execution uncertainty for products that drive medium‑term growth.

Dr. Reddy's Laboratories Ltd. News

Coya Therapeutics to sell 2.522M shares at $4.40 in private placement

Coya Therapeutics (COYA) announced that it has entered into a definitive securities purchase agreement for the purchase and...

18d ago

RDY

COYA

Dr. Reddy’s Posts Q3 FY26 Earnings Call Transcript for Investors

Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ) has provided an update. Dr. Reddy’s Laboratories has notified stock exchanges...

20d ago

Dr. Reddy’s Publishes Audio Recording of Q3 FY2026 Earnings Call

Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ) has issued an update. Dr. Reddy’s Laboratories has notified stock exchanges...

26d ago

Dr. Reddy’s Releases Q3 FY26 Unaudited Results Investor Presentation

Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ) has issued an announcement. Dr. Reddy’s Laboratories Ltd. has released an...

27d ago

Dr. Reddy’s Gets USFDA Post-Application Action Letter for Hyderabad Biologics Plant

An announcement from Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ) is now available. Dr. Reddy’s Laboratories has received...

1M ago

Dr. Reddy’s Laboratories Receives USFDA Observations Post-Inspection

Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ) has issued an update. Dr. Reddy’s Laboratories Ltd. announced that the...

2M ago

Dr. Reddy’s Laboratories to Engage with Investors at Hyderabad Conference

Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ) has issued an announcement. Dr. Reddy’s Laboratories Ltd. has announced its...

2M ago

Midday Fly By: IBM to buy Confluent, Paramount goes hostile for Warner Bros.

The major averages were lower near noon as markets brace for the Federal Reserve’s rate-decision later this week....

2M ago

Immutep, Dr Reddy’s enters strategic collaboration for Eftilagimod Alfa

Immutep (IMMP) and Dr. Reddy’s Laboratories (RDY) announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy’s...

2M ago

RDY

IMMP

Dr. Reddy’s Laboratories Releases Q2 FY26 Earnings Call Transcript

The latest update is out from Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ). Dr. Reddy’s Laboratories Ltd. has...

4M ago

Dr. Reddy’s Laboratories Receives Positive FDA Inspection Outcome

Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ) has issued an announcement. Dr. Reddy’s Laboratories Ltd. announced that the...

4M ago

No jobs report amid shutdown, Apple pulls ICEBlock from App Store: Morning Buzz

The major averages were sharply higher near noon as the U.S. government shutdown marks its third day. There...

5M ago

Esperion reaches settlement agreement with ANDA filer, Dr. Reddy’s

Esperion (ESPR) announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories (RDY) and its...

5M ago

RDY

ESPR

Dr. Reddy’s Laboratories Ensures Compliance with SEBI Regulations

The latest update is out from Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ). Dr. Reddy’s Laboratories Ltd. has...

5M ago

DRREDDY FAQ

What was Dr. Reddy's Laboratories Ltd.’s price range in the past 12 months?

Dr. Reddy's Laboratories Ltd. lowest stock price was ₹1025.90 and its highest was ₹1377.95 in the past 12 months.

What is Dr. Reddy's Laboratories Ltd.’s market cap?

Dr. Reddy's Laboratories Ltd.’s market cap is ₹1.06T.

When is Dr. Reddy's Laboratories Ltd.’s upcoming earnings report date?

Dr. Reddy's Laboratories Ltd.’s upcoming earnings report date is May 08, 2026 which is in 80 days.

How were Dr. Reddy's Laboratories Ltd.’s earnings last quarter?

Dr. Reddy's Laboratories Ltd. released its earnings results on Jan 21, 2026. The company reported ₹14.52 earnings per share for the quarter, beating the consensus estimate of ₹13.763 by ₹0.757.

Is Dr. Reddy's Laboratories Ltd. overvalued?

According to Wall Street analysts Dr. Reddy's Laboratories Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dr. Reddy's Laboratories Ltd. pay dividends?

Dr. Reddy's Laboratories Ltd. pays a Annually dividend of ₹8 which represents an annual dividend yield of 0.63%. See more information on Dr. Reddy's Laboratories Ltd. dividends here

What is Dr. Reddy's Laboratories Ltd.’s EPS estimate?

Dr. Reddy's Laboratories Ltd.’s EPS estimate is 11.82.

How many shares outstanding does Dr. Reddy's Laboratories Ltd. have?

Dr. Reddy's Laboratories Ltd. has 834,591,300 shares outstanding.

What happened to Dr. Reddy's Laboratories Ltd.’s price movement after its last earnings report?

Dr. Reddy's Laboratories Ltd. reported an EPS of ₹14.52 in its last earnings report, beating expectations of ₹13.763. Following the earnings report the stock price went down -0.977%.

Which hedge fund is a major shareholder of Dr. Reddy's Laboratories Ltd.?

Currently, no hedge funds are holding shares in IN:DRREDDY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Dr. Reddy's Laboratories Ltd. (DRREDDY) Earnings & Revenues

Historic Earnings Reports

DRREDDY Stock 12 Month Forecast

Average Price Target

₹1,425.00

▲(11.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1109":"₹1,109","1232":"₹1,232","1355":"₹1,355","1478":"₹1,478","1601":"₹1,601"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.60K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1425,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.43K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.25K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1109,1232,1355,1478,1601],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1253.6,1280.2461538461537,1306.8923076923077,1333.5384615384614,1360.1846153846154,1386.8307692307692,1413.476923076923,1440.123076923077,1466.7692307692307,1493.4153846153845,1520.0615384615385,1546.7076923076922,1573.3538461538462,{"y":1600,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1253.6,1266.7846153846153,1279.9692307692308,1293.1538461538462,1306.3384615384614,1319.5230769230768,1332.7076923076922,1345.8923076923077,1359.076923076923,1372.2615384615385,1385.4461538461537,1398.6307692307691,1411.8153846153846,{"y":1425,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1253.6,1253.3230769230768,1253.0461538461539,1252.7692307692307,1252.4923076923076,1252.2153846153847,1251.9384615384615,1251.6615384615384,1251.3846153846152,1251.1076923076923,1250.8307692307692,1250.553846153846,1250.2769230769231,{"y":1250,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1213.75,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1213.75,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1360.87,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1110.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1145.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1175.54,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1241.23,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1268.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1219.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1280.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1246.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1260,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1253.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >